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Ablation of the cellular prion protein PrPC leads to a chronic demyelinating polyneuropathy (CDP) 
affecting Schwann cells. Neuron-restricted PrPC expression prevents the disease1, suggesting that it 
acts in trans through an unidentified Schwann cell receptor. We found that the cAMP concentration in 
PrPC-deficient sciatic nerves is reduced, suggesting the involvement of a G protein-coupled receptor 
(GPCR). The amino-terminal "flexible tail" (FT, residues 23-120) of PrPC triggered a concentration-
dependent cAMP increase in primary Schwann cells, in the Schwann-cell line SW10, and in Hek293T 
cells overexpressing the GPCR Gpr126/Adgrg6. In contrast, naïve HEK293T cells and HEK293T cells 
expressing several other GPCRs did not react to the FT, and ablation of Gpr126 from SW10 cells 
abolished the FT-induced cAMP response. The FT contains a polycationic cluster (KKRPKPG) 
similar to the GPRGKPG motif of the Gpr126 agonist, type-IV collagen2 (Col4). A KKRPKPG-
containing PrPC-derived peptide (FT23-50) sufficed to induce a Gpr126-dependent cAMP response in 
cells and mice, and improved myelination in hypomorphic Gpr126 zebrafish mutants. Substitution of 
the cationic residues with alanines abolished the biological activity of both FT23-50 and the respective 
Col4 peptide. We conclude that PrPC promotes myelin homeostasis through FT-mediated Gpr126 
agonism. Besides clarifying the physiological role of PrPC, these observations are relevant to the 
pathogenesis of demyelinating polyneuropathies, common debilitating diseases with limited 
therapeutic options.  
Neuronal Prnp ablation triggers CDP1, suggesting the existence of a PrPC receptor on Schwann cells. We 
therefore assessed the binding of full-length PrPC (recPrP, residues 23-231), FT (residues 23-110), or its 
refolded globular domain (GD, residues 121-231), to primary Schwann cell cultures (PSC) from PrnpZH1/ZH1 
sciatic nerves3 using POM1 and POM2 antibodies4. Both recPrP and FT, but not GD, were found to stain 
PSC (Fig. S1A).  
Using transcription activator-like effector nucleases, we generated a Prnp-ablated subclone (termed 
SW10∆PrP) of the SW10 Schwann-cell line (Fig. S1B-C). Again recPrP and FT, but not GD, adhered to 
SW10∆PrP cells (Fig. 1A, S1D-E). Neither recPrP nor FT adhered to the Prnp-/- hippocampal cell line HpL5 
(Fig. S1F), suggesting that binding was specific to Schwann cells. We next measured the binding of 
synthetic PrP-derived peptides (2 µM, 20 min) to SW10∆PrP cells (Fig. 1B). FT23-50, but neither FT39-66 nor 
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any of the carboxy-proximal peptides (Table S1), showed binding (Fig. 1C) suggesting that residues 23-38 
are essential for the interaction. 
We treated SW10 cells with trypsin (2.5% w/v, 10 min) in order to degrade membrane-resident proteins. 
Following trypsin inactivation, we added non-trypsinized SW10 cells labeled with the cell-tracking dye Deep 
Red. HA-tagged FT23-50 (2µM) was added, and binding was monitored with anti-HA antibodies. 51% of non-
trypsinized cells and 5% of trypsinized cells showed FT23-50 binding (Fig. S1G), suggesting the existence of 
a surface FT receptor on Schwann cells. Cytofluorimetry revealed no altered binding of HA-tagged FT23-50 to 
SW10 cells treated with phosphoinositol phospholipase C (PI-PLC, 30' at 37°C), indicating that binding did 
not require GPI-anchored surface proteins, whereas binding of POM2 was greatly reduced indicating that 
PrPC had been stripped from cell surfaces (Fig. S1H). 
Might the FT alter cAMP signaling in Schwann cells? At 4 days of age, PrnpZH1/ZH1 and WT sciatic nerves 
showed similar cAMP levels (Fig. S2A). At 4 weeks of age, PrnpZH1/ZH1sciatic nerves showed a trend 
towards decreased cAMP levels (Fig. S2B). At 12-16 weeks, when CDP is incipient in PrnpZH1/ZH1mice1, 
PrnpZH1/ZH1 nerves exhibited significantly lower cAMP levels (Fig. 1D, p=0.0115). Strictly isogenic 
C57BL/6J PrnpZH3/ZH3 (ref. 6); sciatic nerve lysates from these mice (10-16 week old) also displayed 
significantly lower levels of cAMP than wild-type mice (Fig. S2C).  
Sciatic nerves from 12-16 week old tgNSE-PrP mice, expressing PrPC in neurons, showed cAMP levels 
similar to wild-type mice, whereas tgMBP-PrP sciatic nerves, which express PrPC in Schwann cells and 
suffer from CDP1, showed lower cAMP levels (Fig. 1E). Moreover, when treated with FT (0.1-5 µM; 20 
min), PrnpZH1/ZH1 PSC and SW10 cells displayed a concentration-dependent cAMP increase (Figs. 2A, S2D) 
with an EC50 of 860 nM (Fig. 2B).  
We transfected HEK293T cells, which express little endogenous PrPC, with a plasmid expressing murine 
PrPC or with an empty plasmid (HEKPrP and HEKempty, respectively). Immunoprecipitations showed that 
HEKPrP cells released soluble FT (ca. 37 ng FT/ml, Fig. S3A-B). Exposure to conditioned medium from 
HEKPrP cells, but not from HEKempty cells, raised cAMP levels in PSC cultures generated from PrnpZH1/ZH1 
mice (Fig. 2C). Spent medium from PSC cultures and sciatic nerves from 10-week old C57BL/6 mice did 
not contain any FT, suggesting that little FT is released by Schwann cells (Fig. S3C-D) 
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To assess if the FT contains motifs responsible for inducing the cAMP response, we treated SW10∆PrP cells 
with the same synthetic peptides previously used to assess binding to Schwann cells. Peptide FT23-50 induced 
cAMP, whereas FT34-69 and all carboxy proximal peptides were inactive (Fig. 2D). These results suggest that 
residues 23-33, which contain the lysine-rich "charge cluster 1" (CC1), represent the biologically active 
region of the FT. To test the latter prediction, we incubated FT23-50 with monovalent recombinant phage-
derived miniantibodies recognizing the CC1 (Fab3) or the octapeptide repeats (Fab71) of PrPC. 
Preincubation with Fab3, but not with Fab71, significantly quenched the ability of FT23-50 to induce cAMP in 
SW10∆PrP cells (Fig. 2E).  
Peripheral nervous system myelination is controlled by Gpr126, an adhesion GPCR expressed by Schwann 
cells7,8. We therefore generated HEK293T cells stably overexpressing human Gpr126 or, for control, Gpr124 
and Gpr176 (denoted HEKGpr126, HEKGpr124, and HEKGpr176) with a C-terminal V5 epitope tag9 (Fig. S3E). 
Flow cytometry revealed FT23-50 binding to HEKGpr126 but neither to HEKGpr124 nor to HEKGpr176 cells 
(Fig. 2F-S3F). Moreover, FT23-50 exposure (20'; ≥500 nM) raised cAMP in HEKGpr126 cells but not in 
HEKGpr124 and HEKGpr176 cells (Fig. 3A). We then treated HEK293T, HEKGpr124, and HEKGpr126 cells with 
recombinant FT or GD (2µM, 20’). FT was detected only in HEKGpr126 lysates immunoprecipitated with anti-
V5 antibodies, and GD was never detected (Fig. S4A).  
Next, we generated clonal SW10 cells devoid of endogenous Gpr126 (designated SW10∆Gpr126). When 
treated with FT23-50, SW10 (but not SW10∆Gpr126) cells reacted with increased cAMP levels. A modified 
FT23-50 K→A  peptide (with lysine residues replaced with alanines) was ineffective in binding cells and inducing 
cAMP (Fig. 3B). We then treated SW10∆Gpr126 cells transfected with human Gpr126, Gpr124, Gpr176 or 
Gpr56 with FT23-50. Only Gpr126-transfected cells showed a cAMP response (Fig. S4B) similar to that of 
naïve SW10 cells, indicating that the tag did not affect the function of Gpr126 (Fig. S4C). When treated with 
conditioned media from HEKPrP or HEKempty cells, SW10 but not SW10∆Gpr126 cells responded with a cAMP 
spike (Fig. 3C). Moreover, FT adsorption was reduced in SW10∆Gpr126 cells (Fig. S4D).  
We then administered FT23-50 (2µM, 20’) to HEKGpr126 cells and HEK293(H) cells transfected with plasmids 
encoding human Gpr56, Gpr64, Gpr133, or Gpr97. Only Gpr126-expressing cells showed a cAMP response 
(Fig. S4E). The magnitude of cAMP response was not enhanced by increasing the transfected plasmid, 
suggesting that other signaling components became limiting (Fig. S4F). There was no cAMP induction in 
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PrnpZH1/ZH1 cerebellar granule neuronal cultures treated with FT23-50 or FT23-50 K→A  (Fig. S5A), as expected from 
the minimal Gpr126 expression in the brain10. The FT is released from PrPC by metalloproteases11; after 
treatment with the metalloprotease inhibitor TAPI-2, HEKPrP-conditioned medium contained significantly 
less FT (Fig. S5B-C) and displayed reduced cAMP-inducing activity (Fig. S5B).  
Egr2/Krox-20 controls the expression of myelin genes and is implicated in myelin maintenance12. Egr2 
expression was decreased in 13-week-old PrnpZH3/ZH3 sciatic nerves (p<0.05; Fig. 3D), and recombinant FT 
(2 µM, 24h) activated Egr2-dependent luciferase expression in SW10 cells (Fig. S5D). Similarly, Egr2 
transcription was upregulated in primary Schwann cells treated with recombinant FT (2 µM; 1h) (Fig. S5E). 
Also, Akt phosphorylation increased 5 min after treatment with recombinant FT (2µM) and peaked at 10 min 
in SW10∆PrP but not in SW10∆Gpr126 cells (Fig. S5F-G). The integrity of SW10 cells and their subclones was 
confirmed by the expression of myelin genes (Fig. S6A). 
We identified two regions of similarity between FT (KKRPKPG and QGSPG) and the Gpr126 ligand, Type-
IV collagen (Col4)2 (GPRGKPG and QGSPG, Fig. 4A). Replacement of the conserved cationic residues 
with alanines (KKRPKPG [ AAAPAPG), but not other substitutions, abrogated cAMP induction in 
SW10∆PrP cells (Fig. 4B); treatment with FT23-34 (2µM, 20’), which contains KKRPKPG, sufficed to induce 
cAMP in SW10∆PrP but not in SW10∆Gpr126 cells (Fig. 4C). We next generated murine PrPC mutants 
containing alanine substitutions in either of the two conserved motifs. After transient transfection, both 
mutants were highly expressed by HEK293T cells (Fig. S6B), and cleaved FT was recovered in the medium 
(Fig. S6C). When applied to SW10∆PrP cells, conditioned media from HEK293T cells expressing wild-type 
or QGSPG-mutated PrPC (HEK∑!"#$"PrP ) induced cAMP, whereas medium from cells expressing KKRPK-
mutated PrPC (HEK∑!!"#!PrP ) did not (Fig. S6D). We then generated 21-mer peptides bearing the 
corresponding Col4 sequence (GPRGKPG) or an alanine-substituted variant (AAAGAAG). The native Col4 
peptide (8 µM), but not the mutated peptide, induced cAMP in SW10ΔPrP cells (Fig. S6E).  
In zebrafish, Gpr126 controls myelination, yet Prnp-/- mice have no obvious myelination defects but develop 
a late-onset peripheral neuropathy with demyelination, onion bulb formation (Fig. 5A, S7A), decreased 
Remak bundles containing ≥10 axons and increased bundles containing <10 axons (Fig. S7B), indicative of 
impaired axon-Schwann cell interactions. To test if Gpr126 dysfunction may cause late-onset phenotypes in 
mice, we examined sciatic nerves from DhhCre::Gpr126fl/fl mice experiencing Schwann-cell specific Gpr126 
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ablation from ~E12.5 onwards13,14. At one year of age, we noted neuropathic traits similar to those of Prnp-/- 
mice including reduced bundles containing >20 unmyelinated axons, increased bundles containing <10 
axons, abnormal cytoplasmic Schwann cell protrusions1 and onion bulbs (Fig. 5B and S7C-D).  
The gpr126st63 zebrafish mutant has a point mutation reducing Gpr126 signaling and shows reduced myelin 
basic protein (Mbp) expression by Schwann cells of the posterior lateral line nerve (PLLn) (Fig. 5C, S8A) 
which can be rescued by Gpr126 activators8,15,16. When applied to gpr126st63 zebrafish larvae at 50-55h post-
fertilization (hpf), FT23-50 (20 µM) increased Mbp expression in the PLLn at 5 days post-fertilization (dpf) 
compared to DMSO-treated larvae (Fig. 5C-5D, p<0.05). We also treated gpr126st49 larvae, which encode a 
truncated Gpr126 incapable of Gs signaling8,16. Mbp was barely detectable in both FT23-50 and DMSO-treated 
mutant gpr126st49 larvae (Fig. 5C, S8B). 
We next administered intravenous FT23-50 or FT23-50 K→A  peptide (600 µg) to 10-16 week old PrnpZH3/ZH3 and 
wild-type mice (N=8 per group, all littermates). FT23-50, but not FT23-50 K→A , induced cAMP elevation in both 
PrnpZH3/ZH3 and PrnpZH1/ZH1 sciatic nerves 20 minutes post injection; cAMP reached levels similar to those of 
BL6 mice injected with FT23-50 K→A  (Fig. 5E, S8C). FT23-50 induced a cAMP spike also in the heart, which 
expresses Gpr126 (Fig. 5F, S8D) but not in kidney and brain (Fig. S8E-F) which do not express Gpr12617 . 
Finally, FT23-50 but not FT23-50 K→A  (600 µg) induced a robust cAMP spike in Gpr126fl/fl but not in 
DhhCre::Gpr126fl/fl sciatic nerves (Fig. 5G).  
Here we report the first molecular elucidation of a phenotype caused by PrPC deficiency. While Gpr126 is 
crucial for peripheral nerve myelination during development, the late-onset phenotype of Prnp-ablated mice 
suggests additional roles in myelin maintenance. While Gpr126-/- mice exhibit drastic hypomyelination, the 
Prnp-/- phenotype is relatively mild and late-onset akin to peripheral neuropathies, whose prevalence is 2.4% 
generally and 8% among the aged18. Perhaps Gpr126 provides basal signaling in Prnp-/- mice through its 
interaction with type-IV collagen and/or laminin-211 (ref. 2,16), which may not suffice for long-term myelin 
maintenance. The Gpr126-agonistic properties of systemically administered FT peptides suggests that 
soluble ligands may be beneficial in diseases caused by hypomorphic Gpr126 mutations19, and perhaps also 
in other hereditary motor-sensory neuropathies.  
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A moderately conserved homology region between PrPC and Col4 proved essential to the biological activity 
of both proteins, whereas laminin-211 may activate Gpr126 through different mechanisms. Although Gpr126 
is not expressed in the central nervous system, certain mutants of PrPC cause myelin pathology in vivo20. 
This observation raises the question whether inappropriate GPCR activation may play a role in prion 
diseases within the CNS.  
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Methods 
Mice 
Mice were bred in specified-pathogen free facilities at the University Hospital Zurich and Washington 
University, and housed in groups of 3-5, under a 12 h light/12 h dark cycle (from 7 am to 7 pm) at 21±1°C, 
with sterilized chow (Kliba No. 3431, Provimi Kliba, Kaiseraugst, Switzerland) and water ad libitum. 
Animal care and experimental protocols were in accordance with the Swiss Animal Protection Law, and 
approved by the Veterinary office of the Canton of Zurich (permits 123, 130/2008, 41/2012 and 90/2013). 
The following mice were used in the present study: C57BL/6J, PrnpZH1/ZH1 (ref. 3), co-isogenic C57BL/6J 
PrnpZH3/ZH3 and PrnpWT/WT control mice6 and Schwann cell-specifc DhhCre;Gpr126fl/fl mutants3,4. Mice of both 
genders were used for experiments unless specified. Archival tissues from previous studies1,6 were also 
analyzed in the current study. 
Primary Schwann cell culture 
Sciatic nerves from postnatal day 2-5 were dissected using microsurgical techniques. Nerves were 
dissociated in serum-free DMEM supplemented with 0.05% collagenase IV (Worthington) for 1h in the 
incubator. Sciatic nerves were mechanically dissociated using fire-polished Pasteur pipettes. Cells were 
filtered in a 40 µM cell strainer and washed in Schwann cell culture medium (DMEM, Pen-Strep, Glutamax, 
FBS 10%) by centrifugation at 300g for 10 min. Resuspended cells were plated on 3.5 cm petri dishes 
previously coated with poly-L-lysine 0.01% (wt/vol) and laminin (1 mg/ml). Laminin (Cat. No: L2020; from 
Engelbreth-Holm-Swarm murine sarcoma basement membrane) and poly-L-lysine were obtained from 
Sigma-Aldrich. 
Purification of recombinant proteins 
Full-length recombinant PrP (recPrP, residues 23-231) and globular domain (GD, residues 121-231) were 
purified as previously described21-23. The generation of the GST fusion FT-PrP expression vector (pGEX-KG 
FT-PrP) was described previously; a modified purification protocol was used24. The FT-PrP expression 
vector was transformed into BL21 (DE3) strain of Escherichia coli (Invitrogen). Bacteria were grown in 
Luria-Bertani medium to an OD of 0.6, and the expression of the fusion protein was induced with 0,5mM 
isopropyl-1-thio-β-D-galactopyranoside (AppliChem). Cells were then grown for another 4h at 37 °C and 
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100 rpm shaking. Cells were pelleted at 5000g for 20 min at 4 °C (Sorvall centrifuge, DuPont). The pellet 
was resuspended on ice in lysis buffer (phosphate-buffered saline supplemented with complete protease 
inhibitors (EDTA-free, Roche), phenylmethyl sulfonyl fluoride (Sigma) and 150 µM lysozyme (Sigma) and 
incubated on ice for 30 min. Triton-X 100 (1%), MgCl2 (10mM) and DNase I (5 µg/ml, Roche) were added, 
and the lysate was incubated on ice for 30 min. The lysate was than centrifuged for 20 min at 10’000g at 
4°C. Glutathione sepharose beads were washed with PBS and incubated with the cell lysate for 1h at 4°C on 
a rotating device. Beads were packed into a column and washed with PBS until a stable baseline was reached 
as monitored by absorbance at A280 using an ÄKTAprime (GE healthcare). The fusion protein was cleaved 
on the beads with 5U/ml Thrombin (GE Healthcare) for 1h at room temperature under agitation. For 
thrombin removal, benzamidine sepharose beads were added and incubated for 1h at 4°C on a rotating 
wheel. Protein preparations were analyzed by 12% NuPAGE gels followed by Coomassie- or silver-staining. 
To achieve a higher purity of the protein, we next applied the protein to a sulphopropyl (SP) sepharose 
column equilibrated with 50mM Tris-HCl buffer, pH=8.5. Elution was performed with a linear NaCl 
gradient ranging from 0–1000 mM. Fractions containing the protein were collected and concentrated 
(AMICON; MWCO 3500). The protein was then injected in 500 µl portions into a size-exclusion 
chromatography system (TSK-GEL G2000SWXL column (Tosoh Bioscience)) and eluted with a linear 
gradient using PBS. Pure fractions were combined, concentrated and stored at -20°C. The purity of FT-PrP 
was > 95-98 % as judged by a silver-stained 12% NuPAGE gel. 
Cell Culture 
SW10 cells and clones derived from it were all grown in DMEM medium supplemented with 10% fetal 
bovine serum (FBS), penicillin-streptomycin and Glutamax (all obtained from Invitrogen). HEK293T cells 
and clones derived therefrom were grown in DMEM-F12 medium supplemented with 10%FCS, penicillin-
streptomycin and Glutamax (all obtained from Invitrogen). Human Gpr126 (NM_020455), Gpr124, Gpr64, 
Gpr56, Gpr133, Gpr56 and Gpr176 expression plasmids (pCGpr126-V5, pCGpr124-V5, pCGpr65-V5, 
pCGpr56-V5, pCGpr133-V5, pCGpr56-V5 and pCGpr176-V5) were generated by PCR amplification of the 
respective cDNA followed by TOPO cloning into the pCDNA3.1/V5-His-TOPO vector. The cDNA was in 
frame with the V5 tag (sequence: GKPIPNPLLGLDST) at the C terminus. HEKGPR126, HEKGPR176 cells were 
generated by transfecting 1µg of plasmid in one well of a subconfluent 6-well plate using 3µl Fugene 
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(Roche) according to the manufacturer’s protocol. 24h after transfection, cells were transferred to a 10cm 
dish and grown in selective medium containing 0.4 mg/ml G418 (Invitrogen) until emergence of resistant 
colonies. A limiting dilution was carried out to obtain clonal lines. Membrane expression of the transgene 
was assessed in the selected clones by confocal microscopy using 1:100 diluted anti-V5 antibody 
(Invitrogen) and the Cytofix/Cytoperm kit (Pharmingen Cat. Nr. 554714), according to manufacturer’s 
protocol. 
 
Cerebellar granule neuronal culture: 
Cerebellar granule neurons were generated from 7-8 day old PrnpZH1/ZH1 mice with methods described 
previously25. Cultures were plated at 350,000 cells/cm2 in Basal Medium Eagle (BME) (Invitrogen) with 
10% (v/v) FCS and maintained at 37°C in 5% CO2. 
 
Plasmids and Transfections: 
pCDNA-PrPC was generated by cloning murine PrPC into pCDNA3.1 vector as described previously 26. Site-
specific mutagenesis kit (Stratagene) was used to induce alanine substitutions of QPSPG and KKRPK 
domains in PrPC. Primers used for generating Ala-QPSPG plasmid are: forward- GTG GAA GCC GGT ATC 
CCG GGG CGG CAG CCG CTG CAG GCA ACC GTT ACC C reverse:  GGG TAA CGG TTG CCT GCA 
GCG GCT GCC GCC CCG GGA TAC CGG CTT CCA C. Primers for Ala-KKRPK are: forward- CTA 
TGT GGA CTG ATG TCG GCC TCT GCG CAG CGG CGC CAG CGC CTG GAG GGT GGA ACA 
CCG, reverse: CGG TGT TCC ACC CTC CAG GCG CTG GCG CCG CTG CGC AGA GGC CGA CAT 
CAG TCC ACA TAG. Transfections were performed with Lipofectamine 2000 (Invitrogen) according to 
manufacturer’s protocol. 3µg of DNA was used per well of a 6-well plate. 24h post transfections, cells were 
washed using PBS, and fresh medium was added to the cells.  
 
Immunoprecipitation 
HEK293T and HEKGPR126 cells growing in T75 flasks at 50% density were treated with recombinant FT or 
GD (2µM, 20 min). Cells were washed twice in PBS and lysed in IP buffer: 1% Triton X-100 in PBS, 1x 
protease inhibitors (Roche) and Phospho stop (Roche) for 20 min on ice followed by centrifugation at 5000 
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rpm for 5 min at 4°C. BCA assays were performed to quantify the amount of protein, and 500 µg of protein 
was used for Immunoprecipitations. 2 µg of anti-V5 antibody were added to the cell lysate and incubated on 
a wheel rotator overnight at 4°C. On the following day, Protein G dynabeads (Invitrogen) were added to the 
samples and incubated for further 3h on the wheel at 4°C. Beads were washed three times, 5 min each using 
the IP buffer followed by addition of 2x sample buffer containing DTT (1mM final). Samples were heated at 
95°C for 5 min, loaded on 4-12% Novex Bis-tris gels (Invitrogen), and migrated for 1.5h at 150V followed 
by western blotting. Immunoprecipitations were performed by adding 2 µg of POM2 antibody to 500µl of 
cell medium and incubating overnight on a wheel rotator at 4°C. Protein G beads were then added, and 
incubation on a wheel rotator at 4°C was performed again. 
 
RNA Isolation and quantitative PCR 
RNA extraction and quantitative PCR was performed as described previously1. The following primers were 
used: EGR2 fw: 5’-AATGGCTTGGGACTGACTTG-3’; EGR2 rev: 5’-GCCAGAGAAACCTCCATT-3’ 
CA; GAPDH fw: 5’-CCACCCCAGCAAGGAGAC-3’; GAPDH rev: 5’-GAAATTGTGAGGGAGATGCT-
3’. 
 
Zebrafish mutant strains and analysis:  
Adult zebrafish were maintained in the Washington University Zebrafish Consortium facility 
(http://zebrafishfacility.wustl.edu/) and all experiments were performed in compliance with institutional 
protocols. Embryos were collected from harem matings or in vitro fertilization, raised at 28.5°C, and staged 
according to standard protocols27. The gpr126st49 and gpr126st63 mutants were described previously7,8. 
 
Zebrafish peptide treatment, immunostaining, and quantification: 
gpr126st63 or gpr126st49 mutants were collected from homozygous mutant crosses and WT larvae were 
collected from AB* strain crosses and raised to 50 hours post fertilization (hpf). FT23-50 treatment of gpr126 
mutants was performed as previously described15. Briefly, egg water was then replaced with either 20 µM 
FT23-50 in egg water or egg water containing an equivalent volume of DMSO. At 55 hpf, larvae were washed 
twice and raised in egg water to 5 days post fertilization (dpf). WT and gpr126 larvae were fixed in 2% 
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paraformaldehyde + 1% tricholoroacetic acid in phosphate buffered saline, and Mbp and acetylated tubulin 
immunostaining was performed as described previously8,28. Expression scoring was performed with observer 
blind to treatment according to the following rubric: “strong” = strong and consistent expression throughout 
PLLn, “some” = weak but consistent expression in PLLn, “weak” = weak and patchy expression in PLLn, 
“none” = no expression in PLLn. N = three independent replicate gpr126st63 assays and one gpr126st49 assay. 
n = 87 DMSO-treated gpr126st63 larvae, 81 Prp-FT-treated gpr126st63 larvae, n = 27 DMSO-treated gpr126st49 
larvae, n = 25 Prp-FT-treated gpr126st49 larvae.  
Fluorescent nerve images were analyzed using the Fiji software29. A rectangle region-of-interest (ROI) was 
drawn longitudinally over the fluorescent nerve. The longitudinal grey-scale histogram of the myelin basic 
protein (MBP) was normalized pixel-by-pixel to the corresponding intensity of the acetylated tubulin 
(AcTub). The size of the measured ROIs was kept constant across different treatment modalities.  
  
Flow cytometry 
SW10 cells were grown in P75 flasks at 50% density, rinsed with PBS, and detached from culture flasks with 
dissociation buffer containing EDTA (GIBCO). After detaching, cells were washed to remove residual 
EDTA and counted using a Neubauer chamber. Batches of 105 SW10 cells were transferred to FACS tubes, 
treated with HA-tagged recombinant peptides for 20 minutes, washed, and incubated with Alexa-488 
conjugated anti-HA antibody for 30 minutes. After further washes and centrifugations, cells were 
resuspended in 200µl of FACS buffer (PBS +10% FBS) and analyzed with a FACS Canto II cytofluorimeter 
(BD Biosciences). Data were analyzed using FloJo software. 
 
Western blot analysis 
Schwann cells were lysed in cell-lysis buffer (Tris-HCl 20mM, NaCl 137mM, Triton-X-100 1%) 
supplemented with protease inhibitor cocktail (Roche complete mini). The lysate was homogenized by 
passing several times through a 26G syringe, and cleared by centrifugation at 8000g, 4°C for 2 min. in a 
tabletop centrifuge (Eppendorf 5415R). Protein concentration was measured with the BCA assay (Thermo 
Scientific). 10 µg total protein was boiled in 4 x LDS (Invitrogen) at 95°C for 5 min. After a short 
centrifugation, samples were loaded on a gradient 4-12% Novex Bis-Tris Gel (Invitrogen) for electrophoresis 
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at constant voltage of 200V. Gels were transferred to PVDF membranes with the iBlot system (Life 
technologies). Membranes were blocked with 5% Top-Block (Sigma) in PBS-T for 1h at room temperature. 
Primary antibody was incubated overnight in PBS-T with 5% Top-Block. Membranes were washed three 
times with PBS-T for 10 min. and incubated for 1 hour with secondary antibodies coupled to horseradish 
peroxidase at room temperature. After three washes with PBS-T, the membranes were developed with 
Crescendo chemiluminescence substrate system (Millipore). Signals were detected using a Stella 3200 
imaging system (Raytest, Straubenhardt, Germany). 
 
Antibodies 
Monoclonal antibodies against PrPC were obtained and used as described previously4.  Fab3 and Fab71 
antibodies were generated using the phage display technology and their epitopes were mapped with 
overlapping peptides. Anti AKT, p-AKT were obtained from Cell signaling and used at 1:2000 dilutions for 
western blotting. Anti-p75NGF receptor antibody was obtained from Abcam and used at 1:200 dilutions for 
immunofluorescence. Anti V5 antibody was from Invitrogen and used at a dilution of 1:500 for western blot 
and 2µg of the antibody was used for immunoprecipitation on 500µg of cell lysate. 
 
Cyclic AMP measurements 
In the Direct cAMP ELISA assay, cAMP levels were assessed with a colorimetric competitive immunoassay 
(Enzo Life Sciences). Quantitative determination of intracellular cAMP was performed in cells or tissues 
lysed in 0.1 M HCl to stop endogenous phosphodiesterase activity and to stabilize the released cAMP. SW10 
or HEK293T cells (100’000 cells /well) were plated in 6-well plates to a ca. 50% density. Cells were treated 
with conditioned media or recombinant peptides (2µM, unless specified) for 20 minutes unless otherwise 
mentioned. Cells were lysed with 0.1M HCl lysis buffer (Direct cAMP ELISA kit, Enzo). To ensure 
complete detachment of cells cell scrapers were used. Lysates were homogenized with 26G needle and 
syringe before clearing by centrifugation at 600g for 10 min. The subsequent steps were performed 
according to the manufacturer’s protocol based on competition of sample cAMP with a cAMP-alkaline 
phosphatase conjugate. Cyclic AMP levels were calculated using a cAMP standard curve in the case of 
ELISA based assay. Finally, cAMP concentrations were normalized to total protein content in each sample. 
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cAMP changes are represented as fold changes to the respective controls. For each experiment, at least three 
independent biological replicates were used. For normalization purposes, the median value of the respective 
control sample was defined as “1”. All measurements within each panel were normalized to this control 
value.  
 
Generation of Schwann cell lines devoid of Gpr126  
We designed two CRISPR short-guide RNA (sgRNAs) against exon 2 of Gpr126 (upper Guide 
CCTGTGTTCCTCTCTCAGGT and lower Guide AACAGGAACAGCAGGGCGCT). The DNA sequences 
corresponding to the sgRNAs were cloned into expression plasmids and transfected with EGFP-expressing 
Cas9-nickase plasmids. Single EGFP-expressing Schwann cells were isolated with a FACS sorter (Aria III). 
To determine the exact sequence of indels induced by genome editing we amplified the sgRNA-targeted 
locus by PCR and subcloned the fragments into blunt-TOPO vectors. Ten colonies per cell line were 
sequenced and showed distinct indels on each allele. A clonal subline devoid of Gpr126 was used for further 
studies. This cell line possessed insertions on both the alleles; a 49bp insertion at position 118 and a 5bp 
insertion at position 84 on each allele. Both insertions led to a frameshift and to the generation of premature 
stop codons leading to early translation termination. 
 
Promoter luciferase assay 
Luciferase reporter constructs were generated containing a 1.3kB sequence upstream of the transcription-
starting site of Egr2. SW10 Schwann cells were transfected with Egr2 reporter construct and a renilla 
plasmid using lipofectamine 2000. After one day in vitro, Schwann cells were treated with recombinant full-
length PrP (23-231), the globular domain of PrP (121-231) or PBS control. Luciferase activity was measured 
24 hours after stimulation with Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s recommendations. Results were normalized to renilla transfection controls. 
 
Immunocytochemistry 
Glass coverslips were placed in 12-well plates (Thermo scientific) and coated with 0.01% wt/vol Poly-l-
lysine solution (Sigma) overnight at room temperature. Coverslips were washed three times with ddH2O and 
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dried for 2h in a laminar-flow hood. Schwann cells were seeded and cultured at 50% density. Cells were 
treated with recombinant FT-PrP, full length recPrP or C1-PrP for 20 min., and washed with serum-free 
DMEM. Cells were further washed with PBS followed by fixation with 4% paraformaldehyde. Fixed cells 
were incubated in blocking buffer (PBS+10%FBS) for 1h. Cells were treated with various primary 
antibodies followed by washes and incubation with Alexa 488 and Alexa 647 tagged rabbit or mouse 
secondary antibodies (Life technologies). Imaging was performed by Leica SP2 confocal microscope using a 
20x objective; images were processed by Image J software. 
Transmission electron microscopy 
Transmission electron microscopy was performed as previously described6. Briefly, mice under deep 
anesthesia were subjected to transcardial perfusion with PBS heparin and sciatic nerves were fixed in situ 
with 2.5% glutaraldehyde + 2% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4 and embedded in 
Epon. Ultrathin sections were mounted on copper grids coated with Formvar membrane and contrasted with 
uranyl acetate/lead citrate. Micrographs were acquired using a Hitachi H-7650 electron microscope (Hitachi 
High-Tech, Japan) operating at 80 kV. Brightness and contrast were adjusted using Photoshop. For 
quantification of Remak bundles and onion bulb like structures, images were captured at 1500X 
magnification and axon numbers and abnormal onion bulb like structures were counted manually. 
Quatification was performed in a blinded fashion by assigning numbers to the images and upon completion 
of quantification genotypes were revealed. 
 
Recombinant peptides 
HA-tagged and untagged synthetic peptides were produced by EZ Biosciences. A stock solution of 2mM was 
prepared by dissolving the peptides in PBS and they were used at a final concentration of 2µM unless 
specified. The sequences all the peptides used in this study can be found in Table S1. 
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Figure Legends 
Figure 1. Schwann cells selectively bind the flexible tail (FT) of PrPC. A: Prnp-ablated SW10 cells 
(SW10∆PrP) were exposed to recombinant PrPC, FT, or GD (“ligand”). PrPC and FT, but not GD, adhered to 
Schwann cells (red: POM1 and POM2 antibodies; grey: DAPI). p75NGFR antibodies identified Schwann cells. 
Scale bar: 26 µM. B:  FT-derived peptides and PrPC domains. CC1 and CC2: charge clusters 1 and 2. OR: 
octapeptide repeats. Peptides are color-coded as in panel C. C: SW10∆PrP cells were exposed to FT-derived 
peptides (2 µM; 20 min) carrying a carboxy-terminal hemagglutinin tag (HA). Flow cytometry showed 
strong binding by peptide FT23-50. D: PrnpZH1/ZH1 sciatic nerves displayed lower cAMP than wild-type BL6 
nerves. E: PrPC expression by neurons (tgNSE-PrP), but not by Schwann cells (tgMBP-PrP), restored cAMP 
levels in sciatic nerves of 10-16 week-old mice. Dots: individual mice (11-15 mice/group). N.S.: non-
significant. Error bars: standard error of the mean. Unpaired Student’s t test was used for statistical analysis. 
 
Figure 2. The FT fragment elicits a concentration-dependent cAMP response. A: Primary PrnpZH1/ZH1 
Schwann cells were treated (20’) with increasing concentrations of recombinant FT or with 10 µM GD. Ø: 
untreated cells. cAMP levels were determined in cell lysates (5x105 cells/assay). Addition of FT, but not of 
GD, induced a concentration-dependent cAMP response in Schwann cells. Here and henceforth: *: p<0.05; 
**: p<0.01; ***: p<0.001. B: Primary PrnpZH1/ZH1 Schwann cells (as described in A) were treated with FT 
(20’), and cAMP concentrations were determined by immunoassay. A dose-response curve was interpolated. 
C: cAMP concentrations in primary PrnpZH1/ZH1 Schwann cell cultures exposed to medium conditioned by 
HEK293T cells overexpressing wild-type murine PrPC (HEKPrP, right) or a non-coding vector (HEKempty, 
left) as control. FT-containing medium resulted in cAMP induction. D: Synthetic peptides (27-44 residues) 
were added to SW10∆PrP cells (2 µM each, 20 min). Only FT23-50 induced cAMP. E: FT23-50 was preincubated 
with a two-fold molar excess of miniantibodies Fab3 or Fab71, and added to SW10∆PrP cells (20 min). 
Preincubation with Fab3, but not with Fab71, significantly quenched the FT-dependent cAMP spike. F: HA-
tagged FT23-50 peptide (2µM) was added to wild-type HEK293T (HEKWT) cells or to HEKGPR126 cells, labeled 
with anti-HA antibody, and subjected to cytofluorimetry. Overexpression of Gpr126 increased the binding of 
FT23-50.  
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Figure 3. FT-dependent cAMP signaling in Gpr126-ablated Schwann cells. A: Intracellular cAMP in 
wild-type HEK293T cells and in Gpr176, Gpr124 and Gpr126 overexpressors exposed to FT23-50 (0.5 µM, 
20 min). Only HEKGpr126 cells showed a cAMP increase. B: Wild-type (left) and Gpr126-ablated (right) 
SW10 cells were exposed to FT23-50 (2µM, 20 min). SW10 cells, but not SW10∆Gpr126 cells, respond to FT23-50 
with a cAMP spike. Moreover, SW10 cells did not respond to alanine-substituted FT23-50 (FT23-50 K→A ). C: SW10 
and SW10∆Gpr126 cells were incubated (20 min) with conditioned medium from HEKempty or HEKPrP cells.. 
HEKPrP-conditioned medium induced a robust cAMP spike in SW10, but not SW10∆Gpr126 cells. D: Protein 
was isolated from wild-type or PrnpZH3/ZH3 sciatic nerves (13-week old female mice) and Western blots were 
probed for EGR2 and actin. Densitometry (below) showed reduced Egr2 in PrnpZH3/ZH3 nerves (p=0.028).  
 
Figure 4. FT and collagen-IV share a cAMP-inducing domain. A: Sequence alignment revealed two 
regions of similarity between the FT and Col4 (red boxes). Yellow and green shades represent high and 
moderate similarity, respectively. Dotted line: non-homologous residues. B: SW10∆PrP cells were treated with 
synthetic FT23-50 or modified version of FT23-50 in which the KKRPK or QGSPG motifs were replaced with 
alanines (2µM, 20'). Alanine substitution of KKRPK (peptide FT23-50 K→A ), but not of QGSPG, abrogated cAMP 
induction. C: SW10∆PrP and SW10∆Gpr126 cells were exposed (2µM, 20') to the synthetic peptides FT23-50, 
FT23-34 or SFT23-34 (peptide containing scrambled amino acid sequence of FT23-34). FT23-50 and FT23-34 induced 
cAMP in SW10∆PrP cells but not SW10∆Gpr126 cells.  
 
Figure 5. Myelinotrophic effect of FT in zebrafish and mice. 
A: Transmission electron micrographs from 14 month old wild-type BL6 and PrnpZH3/ZH3 sciatic nerves 
(N=3/4 animals). Thinly myelinated axons (arrowhead), loss of axon-Schwann cell interaction (boxes), 
abnormal cytoplasmic Schwann cell protrusions (white arrowhead) and initial onion bulb formation 
(asterisk) were observed in PrnpZH3/ZH3 mice. Scale bars: 500 nm. B: Neuropathic phenotype of one-year-old 
DhhCre;Gpr126fl/fl mutant mouse nerves. Left panels: toluidine blue-stained sections of sciatic nerves from 
control Gpr126fl/fl (phenotypically wild-type) and DhhCre::Gpr126fl/fl (Gpr126∆Schwann) mice. Gpr126fl/fl nerves 
were well myelinated (N = 3/3 animals), whereas Gpr126∆Schwann nerves exhibited myelin loss with readily 
apparent onion bulb-like structures (arrowheads) (N = 3/3 animals). Right panels: Transmission electron 
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micrographs from Gpr126fl/fl and Gpr126∆Schwann sciatic nerves. Myelinated axons (“M”) and Remak bundles 
(“R”) were found in Gpr126fl/fl sciatic nerves (N = 3/3 animals). Numerous defects were observed in 
Gpr126∆Schwann sciatic nerves (N = 3/3 animals) including onion bulbs (black arrowheads), abnormal 
cytoplasmic protrusions (white arrows), and loss of axon-Schwann cell interactions (boxes) similar to 
PrnpZH3/ZH3 mice. Scale bars = 20 µm (a-b), 2 µm (c-d). C: gpr126st63 hypomorphic mutant larvae were 
treated with vehicle (DMSO) or FT23-50 (20 µM) at 50-55 hours post fertilization (hpf) and posterior lateral 
line nerve was immunostained at 5 days post fertilization (dpf) for myelin basic protein (Mbp, green). 
AcTub: acetylated tubulin (red) labeling axons. Scale bar = 20 µm. The intensity of immunofluorescence 
was assessed by morphometry (right graphs). FT treatment enhanced Mbp immunofluorescence without 
affecting AcTub. D: Mbp expression was scored in larvae treated with FT23-50 or vehicle (DMSO). FT23-50 
treatment resulted in a higher proportion of rescued (“some” and “strong”) MBP expression in gpr126st63 
(53% vs. 34%), but not in gpr126st49 larvae (p < 0.05, Fisher’s two-tailed exact test). N.S. = not significant. 
N ≥ 25 larvae per replicate treatment. E: PrnpZH3/ZH3 and BL6 mice were intravenously exposed to either 
FT23-50 or its non-charged analogue FT23-50 K→A  (600 µg/animal, 20 min). PrnpZH3/ZH3 sciatic nerves showed a 
significant cAMP increase after injection of FT23-50, but not of FT23-50 K→A . FT23-50-treated PrnpZH3/ZH3 sciatic 
nerves reached cAMP levels similar to those of BL/6 mice injected with FT23-50 K→A . Each dot represents an 
individual animal. F: Heart cAMP levels were also increased in FT23-50-injected mice.. G: Control Gpr126fl/fl 
(WT) and DhhCre::Gpr126fl/fl mutant (Gpr126∆Schwann) mice were intravenously injected with either FT23-50 or 
uncharged FT23-50 (FT23-50 K→A ) (600 µg/animal). Sciatic nerves were isolated 20 min post injection. FT23-50 
elicited a significant cAMP increase in WT mice, but not in Gpr126∆Schwann mice. FT23-50 K→A  injection did not 
alter cAMP levels (N=3).  
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Extended Data 
 
Table S1: Sequences of synthetic peptides used in the present study. The collagen-4 homology domain 
necessary for cAMP induction is highlighted in yellow.  
 
Name Sequence 
FT23-50 KKRPKPGGWNTGGSRYPGQGSPGGNRYP 
FT23-50-HA KKRPKPGGWNTGGSRYPGQGSPGGNRYPYPYDVPDYA 
FT34-69-HA PGQGSPGGNRYPPQGGTWGQPKGGGWGQYPYDVPDYA 
FT51-94-HA PQGGTWGQPHGGGWGQPHGGSWGQPHGGSWGQPHGGGW 
FT83-109-HA PHGGGWGQGGGTHNQWNKPSKPKTNLKYPYDVPDYA 
FT94-110-HA GGGTHNQWNKPSKPKTNLKHYPYDVPDYA 
FT94-110 GGGTHNQWNKPSKPKTNLKH 
AlaQGSPG KKRPKPGGWNTGGSRYPGAAAAAGNRYP 
AlaKKRPK AAAPAPGGWNTGGSRYPGQGSPGGNRYP 
ColIV GPRGKPGVDGYNGSRGDPGYP 
ColIV-Mut AAAGAAGVDGYNGSRGDPGYP 
FT23-34 KKRPKPGGWNTG 
SFT23-34 AAAGAAGGWNTG 
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Supplementary Figure Legends 
 
Figure S1. A: Primary Schwann cells were isolated from the sciatic nerves of PrnpZH1/ZH1 mice and grown 
on coverslips. Cells were exposed for 20 min to recombinant PrPC, FT, or GD (2µM), fixed, and stained with 
POM2 (FT, PrPC) or POM1 (GD). Antibodies were visualized in the green channel and nuclei were stained 
with DAPI (blue). PrPC and FT, but not GD, adhered to the cells. Scale bars: 25µm B: Schematic 
representation of the target region for transcription activator-like endonucleases (TALEN) in the Prnp gene. 
Target guides are indicated by arrows. Gene editing resulted in a deletion leading to a frame shift in the PrPC 
coding sequence (designated as conflict in the figure) and a premature stop codon identified by sequencing. 
C: Wild-type SW10 cells and a subclone isolated after treatment with TALEN (termed SW10∆PrP) were 
probed by Western blotting using anti-PrP antibody (POM1). SW10∆PrP showed complete abrogation of PrPC 
expression and was used for further experiments. Levels of actin on the same membrane were monitored to 
confirm equal loading of cell lysates onto the gel. D-E: SW10∆PrP cells were treated with full-length 
recombinant (PrPC, residues 23-231), flexible tail (FT, 23-110), or globular domain (GD, 121-231). PrP 
epitopes were detected with POM2 (D) or POM1 (E) (red). Grey: DAPI. As expected, FT was detected only 
by POM2. Cells were also labeled with antibodies to the p75 nerve-growth factor receptor (yellow), a 
Schwann cell marker. PrPC and FT, but not GD, adhered to Schwann cells. Scale bar: 26 µm. F: the PrPC-
deficient cell line HpL5 was treated with recombinant PrPC, FT, and GD as in panel A. None of the 
recombinant proteins adhered to HpL cells. Scale bars: 20 µm. G: SW10 cells were trypsinized, washed, and 
mixed with non-trypsinized SW10 cells labeled with Deep Red cell tracker. Cells were incubated with HA-
tagged peptide FT23-50, and binding was visualized by flow cytometry. The Deep red signal (abscissa) was 
used to differentiate trypsinized from non-trypsinized cells. 51% of untreated cells, but only 5% of 
trypsinized cells, became decorated by FT23-50-HA, indicating that FT23-50 reacted with trypsin-sensitive 
surface molecules. H: SW10 cells were digested (30 min) with phosphatidylinositol phospholipase C (PI-
PLC, 0.5 units), washed, and incubated with FT23-50-HA along with undigested Deep-Red labeled cells (left 
panel). The proportion of binders in the digested (34%) and the undigested samples (30%) was similar, 
indicating that the FT23-50 receptor was neither PrPC itself nor any other GPI-linked protein. To monitor the 
efficiency of PI-PLC treatment, we assessed POM2 binding to PrPC on both treated and untreated cells (right 
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panel). POM2 binding was significantly decreased in PI-PLC treated cells (23%) compared to untreated cells 
(90%). 
 
Figure S2. A-B: cAMP was measured in sciatic nerves isolated from 4-day old (A) or 4-week old (B) BL6 
and PrnpZH1/ZH1 mice. No difference was observed in cAMP levels in 4-day old mice, whereas 4-week old 
PrnpZH1/ZH1 mice displayed a trend towards decreased cAMP levels. C: Sciatic nerve from 10-week old 
PrnpZH3/ZH3 mice showed a significant decrease in cAMP (p= 0.0151).  D: SW10 cells were seeded in 6 well 
plates and treated (20’) with recombinant FT or GD (10 µM). Addition of FT, but not of GD, resulted in a 
concentration-dependent intracellular cAMP increase.  
 
Figure S3. A: HEK293T cells were transfected with an empty vector (HEKempty) or a plasmid expressing 
murine PrPC (HEKPrP). Cell medium was collected 48h after transfection and subjected to 
immunoprecipitation with monoclonal antibody POM2 (against PrPC), followed by western blotting using 
biotinylated POM2 and streptavidin-HRP. FT was observed only in the medium from HEKPrP cells. B: FT 
released into the conditioned medium of HEKPrP was immunoprecipitated using POM2 and visualized by 
Western blotting with biotinylated POM2. Dilutions of recombinant FT (3.125 - 100 ng) were used for 
calibration, and the concentration of FT released into the medium was estimated at 37 ng/ml. C: Conditioned 
medium from primary BL6 Schwann cells cultures (PSCBL6) was subjected to immunoprecipitation with 
antibody POM2 (against PrPC) followed by Western blotting with POM2. For control, we used conditioned 
medium from HEK cells transfected with a non-coding plasmid (HEKempty) or a with a plasmid encoding 
murine PrPC (HEKPrP). FT was only detected in conditioned medium from HEKPrP cells (lane 2) but not in 
conditioned medium from two independent PSCBL6 cultures (lanes 3-4). Asterisks denote immunoglobulins 
detected by the secondary antibody. D: Sciatic nerves lysates obtained from 10 week old PrnpZH1/ZH1 and 
BL6 mice and subjected to immunoprecipitation with POM2 antibody followed by Western blotting with 
POM2. Full length PrPC, but no FT, was detectable in the immunoprecipitates from BL6 mice. E:  Wild-type 
HEK293T cells (HEKWT) or HEK293T cells overexpressing various GPCRs bearing V5 epitope tags 
(HEKGpr126, HEKGpr124, and HEKGpr176) were grown on coverslips and stained with anti V5 antibody 
(detecting tagged GPCRs; magenta). Nuclei were stained with DAPI (blue). Staining revealed cell surface 
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expression of all transfected GPCRs. Scale bar: 8µm. F: Binding of HA-tagged FT23-50 to HEKGPR126 cells 
(right panel, monitored by cytofluorimetry) was conspicuously increased over that of wild-type, Gpr176, and 
Gpr124-overexpressing HEK293T cells.  
 
  
Figure S4. A: HEK293T, HEKGPR124 and HEKGPR126 cells were exposed (20 min) to recombinant FT, GD 
(2µM), or PBS, and subjected to immunoprecipitation using the anti-V5 antibody, followed by Western 
blotting using POM2, anti-V5 or POM1. Anti-V5 detected both full-length Gpr126, Gpr124 (denoted as 
GprV5 for both proteins) and the respective C-terminal fragments (Gpr126V5-CTF, Gpr124V5-CTF). 
POM2 revealed a band corresponding to the FT (lane 3) that co-precipitated with GPR126. POM1 indicated 
that GD did not bind. Lanes 1, 2 and 3: HEKGPR126 cells treated with PBS, GD and FT. Lanes 4, 5 and 6: 
HEKGPR124 cells treated with PBS, GD and FT. Lanes 7, 8 and 9: HEK293T cells treated with PBS, GD and 
FT Asterisks: immunoglobulin heavy and light chains. B: SW10∆Gpr126 cells plated at a density of 100’000 
cells/well in 6-well plates were transfected with control plasmid (pCDNA3) or plasmids encoding various 
GPCRs (Gpr126, 124, 176, and 56) bearing C-terminal V5 tags. Only cells transfected with pCGpr126-V5 
showed a cAMP response to FT23-50 48h post transfection. PBS treatment was used for control.  C:  
Intracellular cAMP responses to FT treatment (2 µM, 20’) in SW10 and SW10∆Gpr126 cells, as well as SW10∆!"#$%&!"#$%&'( cells expressing V5-tagged human Gpr126 (pCGpr126-V5).  A significant increase in cAMP 
was observed in SW10 cells, whereas SW10∆Gpr126 showed no change. In contrast, SW10∆!"#$%&!"#$%&'( cells 
showed a significant cAMP increase, indicative of successful complementation. D: SW10 and SW10∆Gpr126 
cells were grown on coverslips for 24h and exposed to recombinant FT (2 µM, 20 min). Cells were stained 
with POM2 (detecting FT; red, DAPI-stained nuclei: grey) and antibodies to p75NGFR (yellow). Deletion of 
Gpr126 largely suppressed FT binding. Scale bar: 26 µm. E: HEK293(H) cell lines were transfected with 
plasmids expressing different adhesion GPCRs (Gpr: 97, 133, 64, 56), followed by selection of cells 
expressing the receptor in presence of geneticin. GPCR expressing cells and HEKGpr126 cells were then 
treated with either FT23-50 or FT23-50 K→A  for control (FT and C, respectively). Only cells expressing Gpr126 
responded to FT23-50 with a cAMP spike. Interestingly, cells expressing Gpr133 reacted with a decrease in 
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cAMP levels. F: HEK293T cells were transfected with increasing amounts of human Gpr126 plasmid (2-
5µg/well of a 6 well plate). 48h post transfection cells were treated with FT23-50 or PBS as a control. 
Increasing amount of Gpr126 cDNA did not result in amplification of cAMP signal. 
 
Figure S5. A: Primary PrnpZH1/ZH1 cerebellar granule neuron cultures were seeded in 6-well plates at a 
density of 5x105 cells and treated with FT23-50, FT23-50 K→A , or PBS. No alterations in the levels of cAMP were 
noticed. B: SW10 cells were exposed to conditioned medium from HEK cells that had been transfected with 
empty vector (HEKempty) or a PrPC expression vector (HEKPrP). HEKPrP were optionally treated with 100 µM 
of the TAPI-2 protease inhibitor for 24h before harvesting the medium. TAPI-2 treatment resulted in reduced 
cAMP induction, suggesting that impaired proteolytic cleavage of the FT from PrPC resulted in decreased 
signaling. C: Quantification of FT released into the medium relative to the total amount of PrPC in lysates by 
Western blotting. The spent medium of HEKPrP cells treated with TAPI-2 contained less FT. D: SW10 and 
SW10∆Gpr126 cells were transfected with an Egr2-controlled firefly luciferase reporter and treated with 
recombinant FT (2µM) or PBS (24 hrs). Ordinate: luciferase expression normalized to a renilla luciferase 
control (n=3; *: p<0.05; t-test). Luciferase activity was observed only in SW10 cells stimulated with FT but 
not in SW10∆Gpr126 cells.  E: Primary Schwann cells were exposed to recombinant FT (2 µM, 1h) or PBS. 
Egr2 mRNA expression was measured by quantitative RT-PCR and normalized against a panel of 
housekeeping genes. F: SW10∆PrP and SW10∆Gpr126 cells were grown in 6-well plates, exposed to 
recombinant FT (≤30 min), and analyzed by Western blotting (left). Densitometry (right) showed increased 
phospho-AKT/AKT ratio in SW10∆PrP cells, but not in SW10∆Gpr126 cells. 
 
 
 Figure S6. A:  SW10, SW10∆PrP and SW10∆Gpr126 cells were grown on coverslips and stained with 
antibodies against Myelin associated glycoprotein (MAG), Myelin oligodendrocyte glycoprotein (MOG), 
glial fibrillary acidic protein (GFAP) and p75 nerve growth factor receptor (p75NGFR) (left panel, all green; 
DAPI-stained nuclei: blue). Cells labeled with secondary antibody alone (2° Ab) were used as control to 
determine unspecific staining. Scale bars: 10µm. Expression in all cell lines was confirmed by western 
blotting (right panel). Lysate from HEK293T wild-type cells (HEKWT) was used as control. All proteins 
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except Myelin basic protein (MBP) were expressed in SW10 cells and its derivatives. B: Western blot 
(developed with POM2) of HEK 293T cells transfected with expression plasmids for wild-type murine PrPC 
or for PrPC bearing lysine-to-alanine substitutions in the KKRPK and QGSPG motifs (lanes 3 and 4, 
respectively). The mutations did not affect the biogenesis and processing of PrPC C: Western blot of the 
medium collected from the cells shown in panel B. FT fragments bearing the mutations were released into 
the medium similarly to wild-type FT. D: SW10∆PrP cells were treated with conditioned medium from 
HEK293T cells transfected with an empty vector (HEKempty), with PrPC (HEKPrP), or with full-length PrPC 
versions in which the QGSPG (HEKPrP∑QGSPG) or KKRPK (HEKPrP∑KKRPK) motifs were substituted (∑) with 
alanines. The charge neutralization within the KKRPK motif abrogated the cAMP induction. E: SW10∆PrP 
cells were treated with FT23-50 (2 µM) or a Col4-derived 21-meric synthetic peptide containing either the 
GPRGKPG domain or its alanine-substituted variant (AAAGAAG; both 8 µM). Both FT23-50 and the native 
Col4 peptide, but not the alanine-substituted peptide (Ala-Col4), induced cAMP.  
 
Figure S7. A: Transmission electron micrographs of 14 month-old PrnpZH1/ZH1 sciatic nerves (ZH1). Black 
arrowhead: thinly myelinated axons; white arrowhead: abnormal cytoplasmic Schwann cell protrusions; 
boxes: loss of axon-Schwann cell interactions; asterisk: initial onion bulb formation. Scale bar: 2 µm in 
upper left panel; 500 nm in all other panels. B-C: Quantification of unmyelinated axons in Remak bundles 
was performed manually by counting number of axons in the bundles from electron microscopy images 
(1500x magnification, 10 images per mouse were analyzed and three mice per genotype were used in total). 
The bundles were further sorted into three categories; <10 axons, 10-20 axons and >20axons/bundle. 
Comparisons were performed between either BL6 and PrnpZH3/ZH3 (B) or Gpr126fl/fl (WT) and 
DhhCre::Gpr126fl/fl (Gpr126∆Schwann) mice (all mice were 13 month old in age). Both PrnpZH3/ZH3 and 
Gpr126∆Schwann mice showed a similar inclination towards decrease in number of axons per bundle. Statistical 
significance was established by performing a two-way annova with Bonferroni correction.  D: Onion bulb 
like structures were quantified from electron microscopy images (1500x magnification, 10 images per mouse 
were analyzed and three mice per genotype were used in total) of either BL6 and PrnpZH3/ZH3 or Gpr126fl/fl 
(WT) and DhhCre::Gpr126fl/fl (Gpr126∆Schwann) mice. These onion bulb like structures were prevalent only in 
PrnpZH3/ZH3 and Gpr126∆Schwann  mice, with Gpr126∆Schwann  exhibiting more.  
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Figure S8. A:  Immunofluorescence for myelin basic protein (Mbp; green) in the posterior lateral line nerve 
of wild-type zebrafish larvae. AcTub: acetylated tubulin (red) labels the axons. Scale bar = 20 µm. B: 
gpr126st49 hypomorphic mutant larvae were treated with vehicle (DMSO) or FT23-50 (20 µM) at 50-55 hours 
post fertilization (hpf) and immunostained at 5 days post fertilization (dpf) for myelin basic protein (Mbp, 
green). AcTub: acetylated tubulin (red) labeling axons. Scale bar = 20 µm. FT23-50 treatment did not alter 
Mbp immunofluorescence. C: FT23-50 or FT23-50 K→A  was intravenously administered to PrnpZH1/ZH1 and BL6 
mice (600 µg/mouse, 20 min). After FT23-50 injection, cAMP levels in PrnpZH1/ZH1 mice increased to levels 
approaching those of BL6 mice. Each dot represents an individual animal. D: cAMP spiked also in hearts of 
FT23-50 injected but not in FT23-50 K→A  injected  mice. *: p<0.05; **: p<0.01. C-D: FT23-50 or FT23-50 K→A  was injected 
intravenously into 10-16-week old PrnpZH1/ZH1 or BL6 mice (600 µg/animal, 20 minutes). cAMP levels in 
kidneys (E) and brain (F) showed no significant changes. 
 
Figure S9-S10: Includes the uncropped blots from different figures in the manuscript. All the images were 
cropped in Adobe Photoshop and realigned in Adobe Illustrator. 	
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Figure S5F: Uncropped Blots
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Figure 3D: Uncropped blots
WT PrnpZH3/ZH3-
*
* .
- Marker was loaded in the middle lane denoted by -
at room temperature followed by reblotting with anti actin antibody.
